Weekly Roundup (April 2-April 6, 2012): What We Read Crossing The ‘Bridge

This Week on the DataBridge

As news about clinical studies continued to filter into the DataBridge this week, we made sure to do our part in furthering the conversation with a couple of posts. To kick off the week, we examined the role of cost-effectiveness in the personalized cancer medicine equation. Then, in the middle of the week, we took a look at the future of pharma R&D outsourcing and factors to consider when it comes to virtual outsourcing in biopharma.



Around the Web: Clinical Research News Stories About Pharma R&D Outsourcing and Biotech News

Read on for all the most important news about clinical studies and other pertinent topics from this week ...

One article issued a call for medicine that “allows for customization,” and others report that the cost of prescriptions in the UK will rise. Some feel that a vaccine could be developed to “stop heart attacks,” while others say that predictive innovation is “not a panacea.”

The “first targeted nanomedicine” is set to enter human clinical trials.

An article noted that whole genome sequencing is “not informative for all,” and Forbes takes on America’s Gardasil problem with “how politics poisons public health.” Another outlet took a look at how the pursuit of personalized medicine is impacting companion diagnostics budgets, while a study has indicated that a “change from lab to natural setting” can alter biologic and genetic determinants of behavior.

In biotech news, a piece questioned whether small biotech is the answer for Big Pharma’s “desperation for product.” Also, researchers have uncovered a new “immune defense enzyme,” while a compound has been found to “halt growth” of a malaria parasite.


A Week Dominated by Significant Oncology Study News

In headlines surrounding oncology studies, an article documented the chase for “cheaper cancer drugs,” while another noted that many cancer rates “continue to decline.” DNA sequencing could “lay the foundation” for personalized cancer medicine, and a cancer stem cell vaccine that is in development shows “antitumor effect.”

A study has indicated that “long-term estrogen therapy” could elevate breast cancer risk, and another has identified a link between “inflammation and breast cancer metastases.” Researchers have found that “oxygen in tumors” could predict prostate cancer recurrence, while trials are showing the “promise of a human virus” in treating head and neck cancer patients.

Some are wondering whether pricey cancer drugs can “outlast austerity.”

Elsewhere in oncology study news, new research could “stop tumor cells from spreading,” and vitamin D could “take gas pedal off” prostate cancer. Researchers are looking at a link between a new signaling pathway and breast cancer metastasis, while a DNA marker could indicate whether ovarian cancer treatment “will be successful.”

A study noted that nearly half of cancer survivors died from “conditions other than cancer,” and some wonder whether Chinese medicine can be used in cancer treatment. And finally in developments in oncology studies, arsenic has been found to “turn stem cells cancerous” and spur tumor growth, while a piece examine the “multiple faces” of deadly breast cancer.


So were there any key clinical research news articles that slipped past us this week? Were there any posts or pieces about virtual outsourcing in biopharma or any other intriguing topics that caught your eye?

Please feel free to share your links or observations in the comments section below, and remember to follow us on Twitter and subscribe to our RSS feed for all the latest industry news. Thanks as always for reading the DataBridge, and have a great weekend!